Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Investigation of the effect of hepatic metabolism on off-target cardiotoxicity in a multi-organ human-on-a-chip system.

Oleaga C, Riu A, Rothemund S, Lavado A, McAleer CW, Long CJ, Persaud K, Narasimhan NS, Tran M, Roles J, Carmona-Moran CA, Sasserath T, Elbrecht DH, Kumanchik L, Bridges LR, Martin C, Schnepper MT, Ekman G, Jackson M, Wang YI, Note R, Langer J, Teissier S, Hickman JJ.

Biomaterials. 2018 Nov;182:176-190. doi: 10.1016/j.biomaterials.2018.07.062. Epub 2018 Aug 4.

PMID:
30130706
2.

Self-contained, low-cost Body-on-a-Chip systems for drug development.

Wang YI, Oleaga C, Long CJ, Esch MB, McAleer CW, Miller PG, Hickman JJ, Shuler ML.

Exp Biol Med (Maywood). 2017 Nov;242(17):1701-1713. doi: 10.1177/1535370217694101. Epub 2017 Feb 17. Review.

3.

Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs.

Oleaga C, Bernabini C, Smith AS, Srinivasan B, Jackson M, McLamb W, Platt V, Bridges R, Cai Y, Santhanam N, Berry B, Najjar S, Akanda N, Guo X, Martin C, Ekman G, Esch MB, Langer J, Ouedraogo G, Cotovio J, Breton L, Shuler ML, Hickman JJ.

Sci Rep. 2016 Feb 3;6:20030. doi: 10.1038/srep20030.

4.

A phenotypic in vitro model for the main determinants of human whole heart function.

Stancescu M, Molnar P, McAleer CW, McLamb W, Long CJ, Oleaga C, Prot JM, Hickman JJ.

Biomaterials. 2015 Aug;60:20-30. doi: 10.1016/j.biomaterials.2015.04.035. Epub 2015 May 14.

5.

How multi-organ microdevices can help foster drug development.

Esch MB, Smith AS, Prot JM, Oleaga C, Hickman JJ, Shuler ML.

Adv Drug Deliv Rev. 2014 Apr;69-70:158-69. doi: 10.1016/j.addr.2013.12.003. Epub 2014 Jan 9. Review.

6.

Stability and immunogenicity properties of the gene-silencing polypurine reverse Hoogsteen hairpins.

Villalobos X, Rodríguez L, Prévot J, Oleaga C, Ciudad CJ, Noé V.

Mol Pharm. 2014 Jan 6;11(1):254-64. doi: 10.1021/mp400431f. Epub 2013 Nov 27.

PMID:
24251728
7.

The redox state of cytochrome c modulates resistance to methotrexate in human MCF7 breast cancer cells.

Barros S, Mencia N, Rodríguez L, Oleaga C, Santos C, Noé V, Ciudad CJ.

PLoS One. 2013 May 13;8(5):e63276. doi: 10.1371/journal.pone.0063276. Print 2013.

8.

Cocoa flavanol metabolites activate HNF-3β, Sp1, and NFY-mediated transcription of apolipoprotein AI in human cells.

Oleaga C, Ciudad CJ, Izquierdo-Pulido M, Noé V.

Mol Nutr Food Res. 2013 Jun;57(6):986-95. doi: 10.1002/mnfr.201200507. Epub 2013 Jan 7.

PMID:
23293065
9.

Identification of novel Sp1 targets involved in proliferation and cancer by functional genomics.

Oleaga C, Welten S, Belloc A, Solé A, Rodriguez L, Mencia N, Selga E, Tapias A, Noé V, Ciudad CJ.

Biochem Pharmacol. 2012 Dec 15;84(12):1581-91. doi: 10.1016/j.bcp.2012.09.014. Epub 2012 Sep 25.

PMID:
23018034
10.

Coffee polyphenols change the expression of STAT5B and ATF-2 modifying cyclin D1 levels in cancer cells.

Oleaga C, Ciudad CJ, Noé V, Izquierdo-Pulido M.

Oxid Med Cell Longev. 2012;2012:390385. doi: 10.1155/2012/390385. Epub 2012 Aug 7.

11.

CYP1A1 is overexpressed upon incubation of breast cancer cells with a polyphenolic cocoa extract.

Oleaga C, García M, Solé A, Ciudad CJ, Izquierdo-Pulido M, Noé V.

Eur J Nutr. 2012 Jun;51(4):465-76. doi: 10.1007/s00394-011-0231-2. Epub 2011 Aug 6.

PMID:
21822728
12.

Networking of differentially expressed genes in human cancer cells resistant to methotrexate.

Selga E, Oleaga C, Ramírez S, de Almagro MC, Noé V, Ciudad CJ.

Genome Med. 2009 Sep 4;1(9):83. doi: 10.1186/gm83.

Supplemental Content

Loading ...
Support Center